Bevacizumab:
Is PK the forgotten biomarker?

Cindy SERDJEBI,
SMARTc, INSERM UMR S_911,
Marseille
Bevacizumab (Avastin®)

A variety of settings

A variety of biomarkers

Little is known about PK variability as a confounding factor!
PK variability is not a hoax!

Bevacizumab (Avastin®)

- mCRC Patients (CHU Timone, Pr Seitz)
- NSCLC Patients (CHU Nord, Pr Barlési)

Therapeutic Drug Monitoring (Cmax, Ctrough)
PK variability is not a hoax!

Bevacizumab (Avastin®)

Pt_{12}: unusual and unexpected severe toxs!

Inter-patient variability on drug levels: > 200%!

Chantry, Ciccolini et al., AACR 2014, Ciccolini et al. CCR., in press 2015
TAKE HOME MESSAGE

Beyond testing tumors ...

..... Time for testing patients?

Check the PK, stupid!

Prof. Merrill J. Egorin, UPMC PA USA (1948–2010)